Zimmer Biomet grants 7,050 RSUs to Yi Sang

Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit.

Rhea-AI Filing Summary

Zimmer Biomet Holdings reported that Group President, Asia Pacific, Yi Sang acquired 7,050 restricted stock units (RSUs) at a price of $0.00 per unit. These RSUs were earned from performance-based awards granted in March and September 2023 for the 2023–2025 performance period.

Based on actual performance determined on February 19, 2026, Yi Sang earned 5,298 RSUs from the March 2023 grant and 1,752 RSUs from the September 2023 grant. Each RSU represents a contingent right to receive one share of Zimmer Biomet common stock and the 7,050 RSUs will vest on March 6, 2026.

Insider Trade Summary

Grant/Award: 7,050 shares

Grant/Award 1 txn

Insider Yi Sang

Role Group President, Asia Pacific

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	7,050	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 7,050 contracts (Direct)

Footnotes (2)

1. F1. Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.
2. F2. On March 6, 2023, and on September 1, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023 - 2025. As determined on February 19, 2026, based on actual performance, the reporting person earned 5,298 RSUs for March and 1,752 RSUs for September, totaling 7,050 RSUs, which will vest on March 6, 2026.

FAQ

What insider transaction did Zimmer Biomet (ZBH) report for Yi Sang?

Zimmer Biomet reported that Yi Sang received 7,050 restricted stock units. These units were earned from prior performance-based RSU grants tied to 2023–2025 results and were formally credited on February 19, 2026, at no cash cost per unit.

How many Zimmer Biomet (ZBH) RSUs did Yi Sang earn from each 2023 grant?

Yi Sang earned 5,298 RSUs from the March 6, 2023 grant and 1,752 RSUs from the September 1, 2023 grant. Together they total 7,050 RSUs, reflecting performance achieved over the 2023–2025 performance period defined in the awards.

When do Yi Sang’s 7,050 Zimmer Biomet (ZBH) RSUs vest?

The 7,050 restricted stock units awarded to Yi Sang will vest on March 6, 2026. Vesting means the RSUs convert into Zimmer Biomet common shares, assuming continued satisfaction of any remaining service-based conditions through that vesting date.

What does each RSU in Yi Sang’s Zimmer Biomet (ZBH) grant represent?

Each restricted stock unit represents a contingent right to receive one share of Zimmer Biomet common stock. The units do not involve an exercise price and convert into shares upon vesting, as long as applicable conditions under the RSU agreements are met.

Was cash paid for Yi Sang’s newly earned Zimmer Biomet (ZBH) RSUs?

No cash was paid for these units; the Form 4 lists a price of $0.00 per RSU. The 7,050 RSUs represent equity compensation earned based on company performance over the 2023–2025 period, not an open-market purchase of existing shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/23/2026 - 05:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yi Sang

(Last) (First) (Middle)

345 E. MAIN STREET

(Street)

WARSAW IN 46580

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZIMMER BIOMET HOLDINGS, INC. [ ZBH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Group President, Asia Pacific

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/19/2026		A		7,050(2)		03/06/2026	03/06/2026	Common Stock	7,050(2)	$0	7,050	D

Explanation of Responses:

1. Each RSU represents a contingent right to receive one share of Zimmer Biomet Holdings, Inc. common stock.

2. On March 6, 2023, and on September 1, 2023, the reporting person was granted performance-based RSUs, with the number of RSUs earned to be determined based on the extent to which certain performance conditions were met for a performance period of 2023 - 2025. As determined on February 19, 2026, based on actual performance, the reporting person earned 5,298 RSUs for March and 1,752 RSUs for September, totaling 7,050 RSUs, which will vest on March 6, 2026.

	/s/ Matthew R. St. Louis, Attorney-in-Fact for Sang Yi (power of attorney previously filed)	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.